EDGAR·FLOW

Zymeworks Inc. — Form 8-K

Filed September 23, 2026 · analyzed by the 8-K Agent
8-K ▼ Likely negative significance 78/100
What the filing says
On September 23, 2026, Zymeworks Inc. (market cap ~$649.5M) completed its acquisition of Theravance Biopharma, Inc. via merger. The transaction was financed with $350 million in senior secured notes issued by special purpose entities (Clover Finance Trust and Clover Finance LLC) to fund asset acquisition. The deal includes contingent value rights tied to future royalties and licensing proceeds from ampreloxetine (TD-4208), with holders entitled to receive up to $0.93 per CVR upon first commercial sale in major markets, plus 10% royalties on net sales during a 10-year royalty term (later of patent expiration, regulatory exclusivity expiration, or 10 years post-first sale). The financing carries an 8.25% base interest rate and is secured by all product rights, IP, and cash flows from the Collaboration Agreement with Mylan.
Why this rating

Major M&A with material leverage (~$350M debt on ~$650M market cap) creates refinancing/repayment risk. CVR structure subordinates equity upside but debt burden is substantial relative to company size. Pharmaceutical pipeline execution risk unknown.

Tradability signal
SHORT conviction 40/100 · expected -0.92% over 4 hrs

SHORT (drift): bad news keeps sliding after dissemination — our one persistent measured edge. Similar past filings (27 in this cell) moved +1.78% in the called direction over 4 hrs; shrunk for sample size that's a +0.92% edge. Price is down 0.9% since the filing hit EDGAR — the slide has begun. Exit plan: HARD stop 4.5% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it negative)
before filing · preread
$27.50 ▲ 0.00%
at our read · unknown
$27.50
+10 min · unknown
$27.48 ▼ 0.05%
+30 min · unknown
$26.93 ▼ 2.07%
+1 hr · unknown
$26.79 ▼ 2.58%
+4 hrs · unknown
$26.67 ▼ 3.02%

The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ ZYME · stock on Yahoo Finance ↗

See more from September 23, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.